Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Tarivid IV Infusion Solution.
| Pharmaceutical Form |
|---|
|
Solution for Infusion. |
Ofloxacin, 2 mg/ml.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ofloxacin |
Ofloxacin is a quinolone-carboxylic acid derivative with a wide range of antibacterial activity against both Gram-negative and Gram-positive organisms. The primary mode of action of the quinolones is the specific inhibition of bacterial DNA gyrase. This enzyme is required for DNA replication, transcription, repair and recombination. |
| List of Excipients |
|---|
|
Sodium chloride |
Clear, colourless Type I glass vials with grey chlorobutyl rubber closures and aluminium caps containing either 50 ml, 100ml or 200 ml infusion solution.
Not all pack sizes may be marketed.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0215
28/06/2002
| Drug | Countries | |
|---|---|---|
| TARIVID | Estonia, Hong Kong, Ireland, Japan, Poland, Singapore, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
